BPH

Urology Product Preview: Oral testosterone agent outperforms gel in hypogonadism studyDrugs and devices in the pipeline from Repros Therapeutics, Bavarian Nordic, NxThera, Solace Therapeutics, Generex Biotechnology, Bioniche, OncoCyte, HistoSonics, and Pacific Edge.
BPH guideline adherence: ‘Room for improvement’A retrospective evaluation to determine adherence to the AUA clinical practice guideline for the management of lower urinary tract symptoms/BPH among urologists practicing in an academic setting found generally positive results, but with room for improvement, researchers reported at the AUA annual meeting in Orlando, FL.
5-ARI treatment linked to decline in sexual functionSexual function in men with lower urinary tract symptoms/BPH generally declines over time whether or not they are treated with medication. However, the magnitude of worsening differs depending on the treatment received, according to findings from the Medical Therapy of Prostatic Symptoms study.
Study: Safety, efficacy similar between PVP, TURPPhotoselective vaporization of the prostate is non-inferior to transurethral resection of the prostate in men with benign prostatic obstruction, researchers reported at the European Association of Urology annual congress in Stockholm, Sweden.
‘Lift’ offers durable improvement in LUTS at 2 yearsData from 2 years of prospective follow-up in a multinational study show that the prostatic urethral lift (PUL [UroLift System, Neotract, Inc., Pleasanton, CA]) is a safe procedure that provides durable, clinically meaningful improvement of lower urinary tract symptoms due to BPH, reported Claus G. Roehrborn, MD, at the AUA annual meeting in Orlando, FL.
Urology Product Preview: Testosterone agent meets efficacy endpoint in phase III studiesDrugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.
AUA 2014: Studies shine light on new PCa tests, TRT safetyIn our “Best of AUA” report, Urology Times’ editors and writers present the AUA annual meeting’s take-home messages in 15 therapeutic areas.
Best of AUA 2014: BPH/LUTSRichard K. Lee, MD, MBA, presents the take home messages on BPH/LUTS from the AUA annual meeting in Orlando, FL.
July 2014 New Urology Products and ServicesNew urology products and services from Symtelligence Medical Informatics, LABORIE, Metamark Genetics, the MediSafe Project, and Olympus
Alpha-blockers top choice for first-line LUTS treatmentMost urologists turn to alpha-blockers as first-line treatment for BPH-related lower urinary tract symptoms, while transurethral resection of the prostate remains the most commonly used surgical modality, according to a recent survey.